Lawrence D. Piro, M.D.
Dr. Lawrence D. Piro is a hematology and oncology specialist who is currently affiliated with Cedars-Sinai Marina del Rey Hospital. He received his medical degree from Washington University School of Medicine in St. Louis and completed his residency at Washington University - Barnes-Jewish Hospital. The physician is the President of the Angeles Clinic and Research Institute and has achieved high worldwide recognition for developing new cancer medications. He serves on various committees for malignant diseases such as leukemia and lymphoma. Dr. Lawrence D. Piro has over 20 years of professional experience. He is a frequent guest on television shows such as Barbara Walters, Entertainment Tonight, Extra, The Doctors, and many others.
The medical career of the oncologist began with the study of non-Hodgkin's lymphoma. His breakthrough paper in the New England Journal of Medicine identified that the treatment of hairy-cell leukemia with a single course of Leustatin produced complete remission in 90% of patients and led to its FDA approval. His dedication to lymphoma research continued with work on pivotal trials on Rituxan, the first monoclonal antibody to ever be approved for the treatment of cancer, which revolutionized the treatment of low-grade lymphoma. Over the years, Dr. Lawrence D. Piro has been the recipient of numerous awards, such as Super Doc, Regional Top Doctor, America's Top Doctors for Cancer, and Castle Connolly Regional Top Doctors.
- Aetna Choice POS II
- Blue Shield of California
- First Health PPO
- Great West PPO
- Multiplan PPO
- United Healthcare
- Blue Cross / Blue Shield
- CareFirst BCBS
Education & Training
Washington University School of Medicine in St. Louis
Washington University - Barnes-Jewish Hospital
Publications & Media
2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
Saven, A., Emanuele, S., Kosty, M., Koziol, J., Ellison, D., Piro, L.
Prolonged, complete remission after 2-chlorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia.
Lee, T. C., Miller, W. E., Curd, J. G., Piro, L. D., Saven, A.
Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine.
Saven, A., Piro, L. D., Lemon, R. H., Figueroa, M. L., Kosty, M., Ellison, D. J., Beutler, E.
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Byrd, J. C., Peterson, B., Piro, L., Saven, A., Vardiman, J. W., Larson, R. A., Schiffer, C.
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
Raza, A., Galili, N., Callander, N., Ochoa, L., Piro, L., Emanuel, P., Williams, S., Burris, H., Faderl, S., Estrov, Z., Curtin, P., Larson, R. A., Keck, J. G., Jones, M., Meng, L., Brown, G. L.
A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan, K. D., Emmanouilides, C., Benson, D. M., Hurst, D., Garcia, P., Michelson, G., Milan, S., Ferketich, A. K., Piro, L., Leonard, J. P., Porcu, P., Eisenbeis, C. F., Banks, A. L., Chen, L., Byrd, J. C., Caligiuri, M. A.
Related cord blood banking for haematopoietic stem cell transplantation.
Screnci, M., Murgi, E., Carmini, D., Piro, L., Cinelli, N., Laurenti, L., Iori, A. P., Simone, F., Massari, S., Girelli, G.
Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes.
Krajewski, S., Gascoyne, R. D., Zapata, J. M., Krajewska, M., Kitada, S., Chhanabhai, M., Horsman, D., Berean, K., Piro, L. D., Fugier-Vivier, I., Liu, Y. J., Wang, H. G., Reed, J. C.
Autoantibodies to platelet glycoproteins in patients with disease-related immune thrombocytopenia.
Berchtold, P., Harris, J. P., Tani, P., Piro, L., McMillan, R.
Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo.
Carrera, C. J., Yamanaka, H., Piro, L. D., Lotz, M., Carson, D. A.
Managed oncology care: the disease management model.
Piro, L., Doctor, J.
Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle.
Goodman, M. G., Wormsley, S. B., Spinosa, J. C., Piro, L. D.
Identification of monoclonal immunoglobulins and quantitative immunoglobulin abnormalities in hairy cell leukemia and chronic lymphocytic leukemia.
Hansen, D. A., Robbins, B. A., Bylund, D. J., Piro, L. D., Saven, A., Ellison, D. J.